CVS Caremark Reaches Settlement With FTC in Insulin Pricing Case

Date:

The agreement would mark another step in the FTC’s effort to curb alleged anticompetitive practices in the insulin market.The CVS logo is displayed outside a CVS store in Los Angeles on Aug. 8, 2022. Mario Tama/Getty Images3/24/2026|Updated: 3/24/2026CVS Health’s Caremark has reached a settlement with the federal government in a lawsuit over insulin pricing, the latest of the “Big Three” prescription drug middlemen to strike such a deal.In a joint motion filed on Monday, CVS and the Federal Trade Commission (FTC) said they are seeking to remove the pharmacy company’s subsidiaries—prescription drug benefit manager Caremark and group purchasing organization Zinc—from the case while federal regulators finalize the settlement.

spot_imgspot_imgspot_img

Share post:

More like this
Related

Nike Sued by Consumers for Not Refunding Tariff Costs

Nike sneakers on display at a store in Westfield...

Ford Targets Mass-Market EVs in Direct Challenge to China

A sign with the Ford logo sits in front...

Less Than 11 Percent of New Construction Is in Urban Areas, Report Finds

Construction workers build a home at a new housing...

What Critical Illness Policy Could Mean for Your Financial Future

Critical illness insurance provides cash benefits for major health...